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Although death rates due to common diseases such as
heart disease, stroke and infectious diseases have declined
over the last half-century, there has been only a small
change in cancer mortality rates. The availability of the
draft human genome sequence and a number of technolo-
gical advances now provide us with the opportunity to
explore the genomic landscape of cancer in an unprece-
dented way. Here, we will describe the application of mul-
tiple genomic technologies toward the interrogation of a
number of cancer genomes, in order to discover molecular
determinants of cancer that might be associated with clini-
cal outcome and those that might be candidates for tar-
geted therapy. It is our hope that these data would one
day be translated into clinical practice to improve thera-
peutic decision-making for more knowledge-based clinical
management.
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